Traditional and new laboratory tools along with advances in AI are outlining a new paradigm in human disease modeling. Don't miss this July issue Point of View by Thomas Hartung, MD, PhD , Director, Center for Alternatives to Animal Testing (CAAT).The post The Impact of FDA’s Animal Use Shift on the Future of Preclinical Testing appeared first on GEN - Genetic Engineering and Biotechnology News.